Novartis’s New Eye Treatment Beovu Gets CHMP Nod
Mounts Challenge to Eylea
Novartis has been tipped to regain dominance in AMD, but Bayer/Regeneron have also gained 12-week dosing approval.
You may also be interested in...
After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.
Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.
The 10-year deal aims to use artificial intelligence to map out the cellular biology behind neuroscience and oncology and accelerate drug discovery in another boost to the field.